Association of sST2 with cardiovascular and death endpoints
| Endpoint, n events/n at risk | Adjustments | Continuous per 1 SD of log transformed sST2 | Quartiles of sST2 | |||
|---|---|---|---|---|---|---|
| Q2 versus Q1 | Q3 versus Q1 | Q4 versus Q1 | Trend test | |||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | p value | ||
| Cardiovascular disease 914/7997 | Model 1 | 1.01 (0.94 to 1.09) | 1.02 (0.82 to 1.27) | 1.05 (0.85 to 1.29) | 1.04 (0.85 to 1.29) | 0.623 |
| Model 2 | 1.01 (0.94 to 1.08) | 1.02 (0.82 to 1.27) | 1.05 (0.85 to 1.29) | 1.03 (0.83 to 1.27) | 0.742 | |
| MI 325/7997 | Model 1 | 0.98 (0.87 to 1.11) | 0.85 (0.60 to 1.21) | 0.94 (0.67 to 1.31) | 0.86 (0.61 to 1.21) | 0.547 |
| Model 2 | 0.97 (0.86 to 1.10) | 0.86 (0.60 to 1.21) | 0.93 (0.66 to 1.30) | 0.84 (0.60 to 1.19) | 0.485 | |
| CHD 635/7997 | Model 1 | 1.01 (0.92 to 1.09) | 0.87 (0.67 to 1.12) | 0.98 (0.76 to 1.26) | 0.95 (0.74 to 1.22) | 0.967 |
| Model 2 | 1.004 (0.92 to 1.09) | 0.87 (0..67 to 1.13) | 0.98 (0.76 to 1.25) | 0.95 (0.76 to 1.21) | 0.998 | |
| Stroke 354/7997 | Model 1 | 1.08 (0.94 to 1.23) | 0.89 (0.57 to 1.39) | 0.92 (0.61 to 1.37) | 1.17 (0.79 to 1.72) | 0.473 |
| Model 2 | 1.03 (0.92 to 1.16) | 1.31 (0.91 to 1.89) | 1.15 (0.79 to 1.68) | 1.18 (0.82 to 1.71) | 0.613 | |
| Heart failure 562/7857 | Model 1 | 1.08 (0.98 to 1.19) | 1.00 (0.77 to 1.29) | 0.98 (0.76 to 1.28) | 1.21 (0.93 to 1.58) | 0.152 |
| Model 2 | 1.06 (0.96 to 1.17) | 1.01 (0.77 to 1.31) | 0.98 (0.75 to 1.29) | 1.18 (0.90 to 1.55) | 0.219 | |
| Model 3 | 1.06 (0.96 to 1.16) | 1.00 (0.77 to 1.30) | 0.98 (0.75 to 1.28) | 1.17 (0.89 to 1.53) | 0.248 | |
| MACE 1183/7857 | Model 1 | 1.03 (0.97 to 1.10) | 1.04 (0.86 to 1.24) | 1.03 (0.86 to 1.24) | 1.11 (0.93 to 1.33) | 0.23 |
| Model 2 | 1.02 (0.96 to 1.09) | 1.03 (0.86 to 1.24) | 1.03 (0.86 to 1.23) | 1.10 (0.92 to 1.31) | 0.31 | |
| All-cause mortality 974/7997 | Model 1 | 1.09 (1.01 to 1.19) | 0.92 (0.72 to 1.16) | 1.00 (0.72 to 1.16) | 1.21 (0.95 to 1.53) | 0.054 |
| Model 2 | 1.09 (1.01 to 1.19) | 0.92 (0.73 to 1.17) | 1.00 (0.80 to 1.25) | 1.20 (0.94 to 1.54) | 0.07 | |
The association between sST2 and incident events is explored using continuous and categorical sST2 with quartile 1 as the referent. Model 1 includes adjustment for Framingham risk factors (HDL and nonHDL cholesterol, systolic blood pressure (BP), smoking, prevalent diabetes) and geographic area. Model 2 includes additional adjustment for NT-proBNP (N-terminal Pro-Brain Natriuretic Peptide), eGFR (estimated glomerular filtration rate) and prevalent valvular heart disease. Model 3 includes additional adjustment for hsTroponin I. MI myocardial infarction, CHD coronary heart disease, MACE major adverse cardiac event, endpoint numbers are following exclusions.